- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
- Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
- Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
- Sobi publishes Annual and sustainability report for 2023
Key statistics
As of last trade Swedish Orphan Biovitrum AB (publ) (SOBI:STO) traded at 278.00, -7.95% below its 52-week high of 302.00, set on Feb 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 278.40 |
---|---|
High | 278.60 |
Low | 277.00 |
Bid | 278.00 |
Offer | 278.60 |
Previous close | 278.40 |
Average volume | 422.93k |
---|---|
Shares outstanding | 354.36m |
Free float | 195.56m |
P/E (TTM) | 44.98 |
Market cap | 98.65bn SEK |
EPS (TTM) | 6.19 SEK |
Data delayed at least 15 minutes, as of May 23 2024 08:37 BST.
More ▼